Telmisartan

Generic Name: Telmisartan

Brand Names: Actelsar Hct, Micardis, Micardis-hct, Pritor, Twynsta, Tolura, Kinzalmono (previously Telmisartan Boehringer Ingelheim Pharma KG), Telmisartan Teva Pharma, Telmisartan Actavis

Drug Type: Small Molecule

Chemical Formula: C_₃₃H_₃₀N_₄O_₂

CAS Number: 144701-48-4

Unique Ingredient Identifier: U5SYW473RQ

Background: Telmisartan is an angiotensin II receptor antagonist (ARB) used in the management of hypertension. Generally, angiotensin II receptor blockers (ARBs) such as telmisartan bind to the angiotensin II type 1 (AT1) receptors with high affinity, causing inhibition of the action of angiotensin II on vascular smooth muscle, ultimately leading to a reduction in arterial blood pressure. Recent studies suggest that telmisartan may also have PPAR-gamma agonistic properties that could potentially confer beneficial metabolic effects.

Indication: Used alone or in combination with other classes of antihypertensives for the treatment of hypertension. Also used in the treatment of diabetic nephropathy in hypertensive patients with type 2 diabetes mellitus, as well as the treatment of congestive heart failure (only in patients who cannot tolerate ACE inhibitors).

Associated Conditions: Cardiovascular Events, Diabetic Nephropathy, Heart Failure, Hypertension

Clinical Trials

A Clinical Trial of YMC017 in Hypertensive and Hypercholesterolemic Patients With Metabolic Syndrome

Phase 4

Terminated

Conditions: Metabolic Syndrome

Interventions: Drug: Telmisartan 40mg, 80 mg
Drug: Telmisartan 40mg + Rosuvastatin 20mg
Drug: Rosuvastatin 20mg
Drug: Telmisartan 80mg + Rosuvastatin 20mg

First Posted Date: 2016-11-18

Last Posted Date: 2019-04-12

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 55

Registration Number: NCT02968160

Locations: 🇰🇷
Dongguk University Medical Center, Ilsan, Korea, Republic of

Study of Multiple Oral Dosing to Evaluate the Safety and the Pharmacokinetic Drug-drug Interaction of Telmisartan/Amlodipine and Rosuvastatin in Healthy Male Volunteers

Phase 1

Completed

Conditions: Hypertension and Dyslipidemia

Interventions: Drug: Telmisartan
Drug: Amlodipine
Drug: Rosuvastatin

First Posted Date: 2016-10-14

Last Posted Date: 2016-10-14

Lead Sponsor: Daewon Pharmaceutical Co., Ltd.

Target Recruit Count: 71

Registration Number: NCT02933658

Telmisartan Promotes the Differentiation of Monocytes Into Macrophages M2 in Diabetic Nephropathy?

Not Applicable

Completed

Conditions: Diabetic Nephropathy

Interventions: Drug: Losartan during 6 months
Drug: telmisartan during 6 months
Procedure: blood sample

First Posted Date: 2016-05-11

Last Posted Date: 2022-05-19

Lead Sponsor: Centre Hospitalier Universitaire de Nice

Target Recruit Count: 20

Registration Number: NCT02768948

Locations: 🇫🇷
CHU de Nice, Nice, France

Using Telmisartan With ART During Acute HIV Infection to Reduce the CNS Reservoirs of HIV and Lymph Node Fibrosis

Phase 2

Completed

Conditions: HIV CNS Involvement
Acute HIV Infection

Interventions: Drug: TDF/3TC/EFV + Telmisartan
Drug: TDF/3TC/EFV only

First Posted Date: 2016-04-25

Last Posted Date: 2019-09-19

Lead Sponsor: SEARCH Research Foundation

Target Recruit Count: 21

Registration Number: NCT02750059

Locations: 🇹🇭
SEARCH Thailand, Bangkok, Thailand

Left Atrial Mechanical Function Improvement After Atrial Fibrillation Catheter Ablation

Phase 4

Completed

Conditions: Atrial Fibrillation

Interventions: Drug: Telmisartan 80 mg and amlodipine 5 mg
Drug: Placebo (for telmisartan and amlodipine)

First Posted Date: 2016-04-12

Last Posted Date: 2017-03-22

Lead Sponsor: Research Institute for Complex Problems of Cardiovascular Diseases, Russia

Target Recruit Count: 64

Registration Number: NCT02734355

Triple Therapy Prevention of Recurrent Intracerebral Disease EveNts Trial

Phase 3

Recruiting

Conditions: Intracerebral Haemorrhage (ICH)
Hypertension

Interventions: Drug: telmisartan 20mg, amlodipine 2.5mg, and indapamide 1.25mg
Drug: Placebo

First Posted Date: 2016-03-04

Last Posted Date: 2024-04-22

Lead Sponsor: The George Institute

Target Recruit Count: 1600

Registration Number: NCT02699645

Locations: 🇳🇱
Zuyderland Medical Centre, Heerlen, Netherlands
🇳🇱
Radboud University Medical Center, Nijmegen, Netherlands
🇦🇺
Fiona Stanley Hospital, Murdoch, Western Australia, Australia

and more 62 locations

Telmisartan Plus Exercise to Improve Functioning in Peripheral Artery Disease

Not Applicable

Completed

Conditions: Peripheral Artery Disease

Interventions: Behavioral: Supervised Treadmill Exercise Therapy
Drug: Telmisartan
Other: "No exercise" control group
Drug: Placebo

First Posted Date: 2015-10-30

Last Posted Date: 2023-01-11

Lead Sponsor: Northwestern University

Target Recruit Count: 114

Registration Number: NCT02593110

Locations: 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸
Tulane University, New Orleans, Louisiana, United States
🇺🇸
Ochsner Medical Center, New Orleans, Louisiana, United States